Hologic, Inc. is currently facing investor uncertainty as it navigates a proposed buyout at $79 per share, amid a downgrade from BNP Paribas Exane to 'Neutral' and a revised fair value estimate of $76.60. Stock prices have increased by 16.2%, exceeding sector performance, but with a consensus rating of 'Hold' and Zacks Rank of #4 (Sell), investors remain cautious despite expectations of a 4.9% growth in adjusted EPS. Earlier, Hologic reported a 6.2% year-on-year revenue growth, yet missed EPS expectations for Q1, contributing to the current uncertainty.
Loading timeline…
